SYRS announced that the FDA has granted Fast Track Designation to tamibarotene in combination with azacitidine and venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) with RARA overexpression as detected by an FDA approved test in ad...查看全文
Syros(SYRS)06-05 04:45
$Syros(SYRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-068755 Size: 6 KB 网页链接查看全文
Syros(SYRS)06-08 04:35
$Syros(SYRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-070703 Size: 6 KB 网页链接查看全文
Syros(SYRS)04-23 19:15
$Syros(SYRS)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001193125-24-105892 Act: 34 Size: 556 KB 网页链接查看全文
Syros(SYRS)05-14 18:45
$Syros(SYRS)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0000950170-24-059068 Act: 34 Size: 7 MB 网页链接查看全文
Syros(SYRS)06-05 04:45
$Syros(SYRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-068759 Size: 6 KB 网页链接查看全文
Syros(SYRS)06-07 04:35
$Syros(SYRS)$ 8-K Current report, items 5.02, 5.07, and 9.01 Accession Number: 0001193125-24-156118 Act: 34 Size: 167 KB 网页链接查看全文
Syros(SYRS)04-23 19:05
$Syros(SYRS)$ DEF 14A Other definitive proxy statements Accession Number: 0001193125-24-105876 Act: 34 Size: 1 MB 网页链接查看全文
Syros(SYRS)04-23 19:15
$Syros(SYRS)$ ARS Annual Report to Security Holders Accession Number: 0001193125-24-105901 Act: 34 Size: 1 MB 网页链接查看全文
GreenTech绿科技2021-01-16 19:37
$Syros医药(SYRS)$ 不仅在ARKK和ARKG两只基金同时布局,而且对于一个只有不到8亿市值的公司,ARK总共投入了1.13亿美元,这意味着什么呢?查看全文
奕维科技2020-12-05 16:37
除了斗鱼,女神这周也一直在卖$赛里斯治疗(MCRB)$ ,$ExOne(XONE)$ 和$Syros医药(SYRS)$ ,说起XONE,我很多年前还买过,一直不怎么涨~查看全文
chuminhua2019-10-25 22:11
10/24,Syros Pharmaceuticals公司$Syros医药(SYRS)$ 宣布,其选择性视黄酸受体α(RARa)激动剂SY-1425,与低甲基化剂azacitidine联合,在治疗新确诊的急性髓系白血病(AML)患者的2期临床试验中获得积极试验数据。在RARA生物标志物呈阳性的AML患者亚组中,62%的患者达到完全缓解(CR),82%的患...查看全文
chuminhua2019-10-18 12:23
10/17,Syros Pharmaceuticals$Syros医药(SYRS)$ 表示,将优先开发高选择性口服CDK7抑制剂SY-5609,并停止静脉CDK7抑制剂SY-1365的进一步开发。预计2020Q1启动SY-5609治疗实体瘤的I期研究。网页链接查看全文
淘沙见金2017-12-11 05:22
$Syros Pharmaceuticals, Inc.(SYRS)$ 一般来说,公司在摘要里面不提efficacy的数据,说明efficacy一般比较差。不过像SYRS这么差的数据也比较少见,周一应该有一阵血雨腥风了。查看全文
智通财经APP获悉,因塞特(INCY.US)已经终止了与Syros Pharmaceuticals(SYRS.US)在骨髓增生性肿瘤治疗方面的发现和研究合作。终止协议将在8月9日起60天内生效。 2018年1月,因塞特和Syros Pharmaceuticals首次签署了一项合作协议。作为合... 网页链接
$Syros(SYRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-080480 Size: 4 KB 网页链接
$Syros(SYRS)$ 144 Report of proposed sale of securities Accession Number: 0001973141-24-000326 Act: 33 Size: 4 KB 网页链接
$Syros(SYRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-070708 Size: 7 KB 网页链接
$Syros(SYRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-070701 Size: 7 KB 网页链接
$Syros(SYRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-070703 Size: 6 KB 网页链接
$Syros(SYRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-070713 Size: 6 KB 网页链接
$Syros(SYRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-070711 Size: 6 KB 网页链接
$Syros(SYRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-070714 Size: 6 KB 网页链接
$Syros(SYRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-070704 Size: 8 KB 网页链接
$Syros(SYRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-070706 Size: 6 KB 网页链接